7th Eurasian Hematology Oncology Summit
E

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121? Does Idecabtagene Vicleucel Improve ORR? Is Orvacabtagene Autoleucel Safe and Tolerable?

By 7th Eurasian Hematology Oncology Summit FEATURING Evangelos Terpos
December 11, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

26:48
Bristol Myers Squibb Hematology

Expert Discusses Data for a RRMM Regimen

Feat. K. Shain

Related Content

AUTOPLAY
26:18
Morie Gertz

Treatment of Relapsed Myeloma: Overview of Approved Drugs & Optimal Se…

14:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

MRD in Multiple Myeloma Isn't Ready for Prime Time: More Patients Can …

Feat. T. Martin
08:15
2018 Pan Pacific Lymphoma Conference

Evolution of Myeloma Induction Regimens

Feat. S. Holstein
25:51
KU ASH 2018 Review: Current Updates in Hematologic Diseases

MM - Overview of Trials Presented at ASH 2018

Feat. A. Abdallah
05:09
Association of Community Cancer Centers (ACCC)

72 y/o Woman With IgG Lambda High-Risk Multiple Myeloma (del17p): Disease …

Feat. K. Maples
06:31
2nd SOHO Italian Conference

Treatment Options for the R/R MM Patients: A Review of the Current Data

Feat. K. Anderson
13:23
Parameswaran Hari

CAR T and NK Cell Therapy in Myeloma

12:53
2nd SOHO Italian Conference

Genetic Profiling in MM: Can Genomics Help With High-Risk Disease? How Can…

Feat. N. Bolli
17:44
UChicago CAR T-Cell Symposium 2019

Current Grading and Management Strategies of CAR-T Toxicities: Cytokine Re…

Feat. S. Kosuri
04:41
Joshua Richter

Examining Triplet Therapy in MM: Analysis of ELOQUENT-3 and MAIA Trials

25:24
Extracellular Vesicles and Their Role in Patients With Multiple Myeloma

Biologically Based Therapies for MM: Surveying Novel Options

Feat. K. Anderson
22:47
UChicago CAR T-Cell Symposium 2019

Patient Selection for CAR T-Cell Therapy: Therapeutic Benefits, Discussion…

Feat. M. Leukam
11:31
i3 Health

Optimizing Treatment Sequencing for Patients With Relapsed/Refractory Mult…

Feat. S. Kumar
23:48
UChicago CAR T-Cell Symposium 2019

2019 Update on CAR-T in Multiple Myeloma - Can We Improve Upon These Resul…

Feat. J. Jasielec
05:33
Baptist Health South Florida CME

2021 Advancements in Blood Cancers: Blinatumomab in ALL, Pre-ASCT Inductio…

Feat. G. Koehne
09:50
Nina Shah

Maximizing the Initial Gains in Myeloma Therapy: Consolidation and Mainten…

06:21
Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Relapsed/Refractory: CAR T Cells - A New Frontier in Im…

Feat. F. Anwer
12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/Refract…

Feat. M. Dimopoulos
12:03
Andrew Cowan

BCMA CAR-T + Gamma Secretase Inhibitor Appear to Be Well Tolerated in R/R …

27:06
UChicago CAR T-Cell Symposium 2019

Why Does CAR T-Cell Therapy Fail? An Update on Mechanisms of Resistance/Re…

Feat. J. Kline